These managers cannot simply imitate the management styles of other corporate practices, but must develop their own management philosophy compatible with the special nature of the biotechnology ...

After calling Rockville, Maryland, home for more than eight years, Big Pharma GSK is planning to move its vaccine and ...

NEW YORK, NY / ACCESS Newswire / February 9, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...

CEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over £31 billion, with specialty medicines driving performance. Core operating profit grew 13%, supporting a ...

In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against the other stocks. The stock market extended its winning streak on Wednesday, closing firmer as investors ...

The lawsuit claims GlaxoSmithKline replaced Flovent with an identical generic version, hurting patients whose insurance wouldn't cover it and costing taxpayers money. Arizona Attorney General Kris ...

It came as the boss of the London-listed firm cheered an ‘excellent’ performance in 2024. GSK has increased its long-term sales guidance amid hopes for a boost from new speciality medicines ...

When drug companies manipulate the system to increase profits, patients suffer. Arizona Attorney General Kris Mayes is right to take GlaxoSmithKline to court over its decision to discontinue Flovent, ...

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth? The content of this article is ...

Eli Lilly made a $2.5 billion deal for a breast cancer drug; GSK reached a $1 billion-plus deal for IDRx. The announcements suggest a potential rebound in M&A deals in the healthcare sector for 2025.

Brand New Membership Level: Benzinga Trade Alerts GSK plc GSK expects strong momentum in the specialty business segment to continue with growth from existing assets. At the JPMorgan Healthcare ...

Following GSK’s deal-heavy end to 2024, Chief Scientific Officer Tony Wood, Ph.D., doesn’t expect the trend to let up in the new year, zeroing in on partnerships that can expand knowledge ...